Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The company has assembled a wide array of robotic platforms, and it spun out its dental and spine businesses in 2022.
Last trade$102.98
Day change+$1.57 (+1.55%)
Day range$101.42 – $104.44
Volume1,747,127
Market cap$19.19B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$19.19B
Price / earnings
25.01×
Price / book
1.51×
Price / sales
2.24×
EV / sales
3.07×
EV / EBITDA
10.84×
Profitability
Earnings per share
$4.05
Return on assets
3.26%
Return on equity
6.04%
Dividend yield
0.97%
Liquidity and leverage
Debt / equity
0.59×
Current ratio
1.46×
Quick ratio
0.79×
Cash ratio
0.11×
Cash flow
Price / cash flow
10.18×
Price / free cash flow
14.82×
Free cash flow
$1.29B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ZBH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.06B
$2.18B
$2.09B
$2.24B
$2B
$2.08B
$1.91B
$2.02B
Cost of revenue
$760.5M
$635.5M
$576.2M
$792.4M
$735.8M
$592.2M
$549.8M
$586.7M
Gross profit
$1.3B
$1.54B
$1.51B
$1.45B
$1.27B
$1.49B
$1.36B
$1.44B
Selling, general and administrative
$855M
$899.3M
$849.9M
$872.3M
$811.4M
$814.8M
$758.8M
$746.9M
Research and development
$105.9M
$104.8M
$103.4M
$118.7M
$115.9M
$113.3M
$110.6M
$108.5M
Total operating expenses
$994.9M
$1.22B
$1.14B
$1.3B
$914.3M
$1.19B
$1.07B
$1.05B
Operating income
$307.5M
$326.1M
$373.2M
$154.5M
$351.3M
$300M
$292.3M
$388.9M
Interest expense
-$74.9M
-$72.9M
-$68.8M
-$71.9M
-$75.4M
-$79.3M
-$66.2M
-$61.9M
Income before taxes
$230.1M
$255.1M
$301.4M
$98M
$279.2M
$224.6M
$229M
$289M
Income taxes
$37.2M
$55.5M
$63M
-$39.9M
$48M
$71.2M
$46.5M
$48.9M
Net income
$192.9M
$199.6M
$238.4M
$137.9M
$231.2M
$153.4M
$182.5M
$240.1M
Net income attributable to common shareholders
$191.6M
$198.3M
$238.2M
$139.3M
$230.9M
$152.8M
$181.9M
$239.5M
EBITDA
$603.9M
$626.7M
$649.5M
$544.8M
$656.3M
$589.3M
$582.7M
$673.4M
Basic earnings per share
$1.01
$1.03
$1.22
$0.71
$1.17
$0.77
$0.92
$1.20
Diluted earnings per share
$1.00
$1.03
$1.22
$0.70
$1.16
$0.77
$0.91
$1.20
Recent news
Company coverage with links to the original publishers.
Zimmer Biomet (ZBH), a musculoskeletal healthcare company, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a VGM Score of B. The stock has gained 24.5% over the past four weeks with a Momentum Style Score of A, driven by two analyst earnings estimate revisions higher for fiscal 2026.
The ANZ dental implants market is valued at USD 266.0 million in 2025 and is projected to reach USD 393.0 million by 2033, growing at a 5.0% CAGR. Growth is driven by aging populations, increased demand for prosthetics, and technological advances in implant materials. However, high treatment costs remain a significant barrier to market expansion, with 28% of Australians delaying dental care due to affordability concerns.
Zimmer Biomet reported Q3 2026 earnings of $1.90 per share, slightly beating consensus estimates of $1.89, with revenues of $2.06 billion exceeding expectations by 0.81%. However, the stock has underperformed the S&P 500 year-to-date, gaining 7.9% versus the market's 10.6%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 37% of Zacks industries.
Zimmer Biomet is set to report Q3 2026 results on Nov. 4 with revenues expected to grow 2.2% to $2.05 billion, while EPS is projected to decline 0.5% year-over-year. The company faces headwinds from legacy implant phaseouts and international market pressures, particularly in China, though new product adoption and the Paragon 28 acquisition are expected to provide growth support across multiple segments.
Zimmer Biomet (ZBH) is identified as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' Value grade. The company trades at a P/E ratio of 11.98, below its industry average of 15.93, and demonstrates solid valuation metrics across P/B and P/CF ratios, suggesting it may be undervalued relative to its earnings outlook.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 30, 2026
$0.24
Oct 30, 2026
recurring
Jun 25, 2026
$0.24
Jul 31, 2026
recurring
Mar 31, 2026
$0.24
Apr 30, 2026
recurring
Dec 30, 2025
$0.24
Jan 30, 2026
recurring
Sep 30, 2025
$0.24
Oct 31, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.